Correlative single photon emission computed tomography imaging of [123I]altropane binding in the rat model of Parkinson's

Gleave, Jacqueline A.; Farncombe, Troy; Saab, Chantal; Doering, Laurie C.

doi:10.1016/j.nucmedbio.2010.12.006

Cited by 13 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study, conversely, does confirm previous findings of correlation between striatal DAT tracer or FD uptake and striatal dopamine content. SPECT studies of DAT radioligands in rodents with nigrostriatal injury demonstrated a correlation between DAT binding and striatal dopamine . Another study reported a strong correlation between striatal dopamine and striatal FD uptake in MPTP‐treated monkeys .…”

Section: Discussionmentioning

confidence: 98%

“…SPECT studies of DAT radioligands in rodents with nigrostriatal injury demonstrated a correlation between DAT binding and striatal dopamine. 18,19 Another study reported a strong correlation between striatal dopamine and striatal FD uptake in MPTP-treated monkeys. 15 Finally, a study in PD patients found a correlation between striatal FD uptake and amphetamine-induced raclopride displacement, an indirect measure of displaceable striatal dopamine.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of nigrostriatal positron emission tomography measures: Critical limits

Karimi

Tian

Brown

et al. 2013

Annals of Neurology

View full text Add to dashboard Cite

Objective Molecular imaging and clinical endpoints are frequently discordant in Parkinson disease (PD) clinical trials raising questions about validity of these imaging measures to reflect disease severity. We compared striatal uptake for 3 PET tracers with in vitro measures of nigral cell counts and striatal dopamine in MPTP treated monkeys. Methods Sixteen macaques had MRI and baseline PETs using 6-[18F]fluorodopa (FD), [11C] dihydrotetrabenazine (DTBZ) and [11C] 2beta-carbomethoxy-3beta-4-fluorophenyltropane (CFT). MPTP (0 to 0.31 mg/kg) infused unilaterally via the internal carotid artery produced stable hemiparkinsonism by three weeks. After eight weeks, PETs were repeated and animals euthanized for striatal dopamine measurements and unbiased counts of tyrosine hydroxylase stained nigral cells. Results Striatal uptake for each radiotracer (FD, DTBZ, CFT) correlated with stereologic nigral cell counts only for nigral loss < 50% (r2= 0.84; r2= 0.86; r2= 0.87, p<0.001 respectively; n=10). In contrast, striatal uptake correlated with striatal dopamine over the full range of dopamine depletion (r2= 0.95; r2= 0.94; r2= 0.94, p<0.001; n=16). Interestingly, indices of striatal uptake of FD, DTBZ and CFT correlated strongly with each other (r2=0.98, p<0.001). Interpretation Tracer uptake correlated with nigral neurons only when nigral loss < 50%. This along with previous work demonstrating that nigral cell counts correlate strongly with parkinsonism ratings may explain discordant results between neuroimaging and clinical endpoints. Furthermore, strong correlations among striatal uptake for these tracers support lack of differential regulation of decarboxylase activity (FD), vesicular monoamine transporter type 2 (DTBZ), and dopamine transporter (CFT) within 2 months after nigrostriatal injury.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Validation of nigrostriatal positron emission tomography measures: Critical limits

Karimi

Tian

Brown

et al. 2013

Annals of Neurology

View full text Add to dashboard Cite

show abstract

“…Furthermore, it is suggested that [ 123 I]-2 β -carbomethoxy-3 β -(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane ([ 123 I]altropane) can be used to identify DAT. This suggests that SPECT-[ 123 I]altropane is a specific marker to measure dopaminergic content for functional verification [33]. …”

Section: Stem Cell Trackingmentioning

confidence: 99%

In Vivo Assessment of Stem Cells for Treating Neurodegenerative Disease: Current Approaches and Future Prospects

Song

2017

Stem Cells International

View full text Add to dashboard Cite

In recent years, stem cell-related therapies have been widely applied for treating neurodegenerative disease. Despite their potential, stem cell tracking and imaging techniques for the evaluation of in vivo proof-of-concept (PoC) therapies have not been sufficiently represented in the research area. This review summarizes the recent approaches that have been used for tracking and imaging engrafted stem cells in vivo. Furthermore, we introduce tissue clearing technology that can be applied to develop three-dimensional in vivo experiments. Monitoring stem cell survival and migration and graft-host relationships is a useful strategy to evaluate the therapeutic efficacy of regenerative medicine approaches in neurodegenerative disease.

show abstract

“…Initially, single-pinhole SPECT systems were used to image DAT [91, 100], and the SPECT images were coaligned with MR images (or templates) acquired on clinical MRI scanners (using dedicated coils), with or without the use of external markers [99, 101, 102]. Another recent study, however, used a preclinical system with high-resolution parallel-hole collimators (X-SPECT system) to evaluate DAT loss (using [ 123 I]altropane as a radiotracer) in a rat model of PD, and the SPECT images were registered with CT images [103]. Another DAT ([ 123 I]FP-CIT) SPECT study in a mouse model of PD used a double-headed gamma camera equipped with a multipinhole aperture.…”

Section: Applications Of Spect Combined With Ct or Mrimentioning

confidence: 99%

The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI

Bernsen

Vaissier

Holen

et al. 2014

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Preclinical imaging with SPECT combined with CT or MRI is used more and more frequently and has proven to be very useful in translational research. In this article, an overview of current preclinical research applications and trends of SPECT combined with CT or MRI, mainly in tumour imaging and neuroscience imaging, is given and the advantages and disadvantages of the different approaches are described. Today SPECT and CT systems are often integrated into a single device (commonly called a SPECT/CT system), whereas at present combined SPECT and MRI is almost always carried out with separate systems and fiducial markers to combine the separately acquired images. While preclinical SPECT/CT is most widely applied in oncology research, SPECT combined with MRI (SPECT/MRI when integrated in one system) offers the potential for both neuroscience applications and oncological applications. Today CT and MRI are still mainly used to localize radiotracer binding and to improve SPECT quantification, although both CT and MRI have additional potential. Future technology developments may include fast sequential or simultaneous acquisition of (dynamic) multimodality data, spectroscopy, fMRI along with high-resolution anatomic MRI, advanced CT procedures, and combinations of more than two modalities such as combinations of SPECT, PET, MRI and CT all together. This will all strongly depend on new technologies. With further advances in biology and chemistry for imaging molecular targets and (patho)physiological processes in vivo, the introduction of new imaging procedures and promising new radiopharmaceuticals in clinical practice may be accelerated.

show abstract

Correlative single photon emission computed tomography imaging of [123I]altropane binding in the rat model of Parkinson's

Cited by 13 publications

References 22 publications

Validation of nigrostriatal positron emission tomography measures: Critical limits

Validation of nigrostriatal positron emission tomography measures: Critical limits

In Vivo Assessment of Stem Cells for Treating Neurodegenerative Disease: Current Approaches and Future Prospects

The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI

Contact Info

Product

Resources

About